Core Points - Genomma Lab Internacional, S.A.B. de C.V. has declared a cash dividend of $0.20 Mexican pesos per share, totaling $200 million pesos, payable to shareholders on June 21, 2024 [8] - The dividend per share represents a 2% increase compared to the previous quarter, attributed to the cancellation of 20 million shares approved at the last Annual General Shareholders Meeting (AGSM) [1][3] - The company intends to make dividend payments on a quarterly basis, subject to the terms established by the AGSM [4] Company Overview - Genomma Lab is one of the fastest-growing pharmaceutical and personal care products companies in Latin America, developing and marketing a wide range of premium branded products that are leaders in their respective categories [5] - The company operates a sound business model characterized by a unique combination of new product development, consumer-oriented marketing, a broad retail distribution network, and a low-cost, flexible supply chain [5] - Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "LABB" [5]

SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSAXT system from Carterra®, a leading provider of high-throughput large and small molecule screening and characterization solutions. This instrument will enable Standard BioTools™ to further validate its SomaScan® Platform by measuring the kinetic properties of SOMAmer® Reagents and deliver precise information about protein binding and biomarker chara ...

Core Insights - Standard BioTools Inc. has acquired the LSAXT system from Carterra to enhance the validation of its SomaScan Platform, which focuses on measuring kinetic properties of SOMAmer Reagents and providing detailed information on protein binding and biomarker characterization [1][2][3] Company Overview - Standard BioTools Inc. (Nasdaq:LAB), formerly known as Fluidigm Corporation, specializes in next-generation technologies that aid biomedical researchers in developing medicines more efficiently. The company utilizes proprietary mass cytometry and microfluidics technologies to deliver reliable insights in health and disease [4] - Carterra is a leading provider of high-throughput technologies aimed at accelerating the discovery of novel therapeutic candidates. Its LSAXT system is designed to deliver significantly higher throughput and efficiency compared to existing platforms [6] Product and Technology Details - The SomaScan Platform is a high-throughput proteomics technology that allows comprehensive analysis of proteomic biomarkers, enhancing the research capabilities for scientists [2] - The LSAXT system will be instrumental in verifying the quality of SomaScan 11K Assay reagents and will support future content expansion of the platform, thereby increasing its value to researchers [2][3] - The LSAXT system is noted for its ability to provide more data in a shorter time frame, which will help Standard BioTools identify precise binding sites on proteins and discover new biomarkers [3] Leadership Statements - The CEO of Carterra expressed enthusiasm about the collaboration with Standard BioTools, emphasizing the importance of measuring kinetic properties for a deeper understanding of reagent-protein interactions [3] - The President and CEO of Standard BioTools highlighted the focus on ensuring precision and specificity in the SomaScan Platform, which will be enhanced by the capabilities of the LSAXT system [4]

Group 1 - Standard BioTools Inc. will participate in several investor conferences in June 2024, including the Jefferies Global Healthcare Conference and the TD Cowen's 3rd Annual Tool/Dx Revolution Conference [1][4] - The company is known for its portfolio of next-generation technologies that aid biomedical researchers in developing medicines more efficiently [2] - Standard BioTools focuses on providing insights in health and disease through its proprietary mass cytometry and microfluidics technologies, addressing needs in translational and clinical research, particularly in oncology and immunology [2] Group 2 - The President and CEO, Michael Egholm, PhD, will engage in a fireside chat at the Jefferies Global Healthcare Conference on June 5th and participate in a panel discussion at the TD Cowen's conference on June 25th [4] - The company has a strong presence in various research sectors, including academic, government, pharmaceutical, and biotechnology, emphasizing its role in improving patient outcomes [2]

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools") (Nasdaq:LAB) today announced that its management team will participate in the following investor conferences in the month of June: Available presentations will be webcast live and available on the Investor Relations page of the Company's website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com. About Stan ...

Group 1 - Standard BioTools Inc. granted an equity award of 207,832 restricted stock units (RSUs) to a new employee as an inducement for employment, effective May 20, 2024 [1] - The RSUs will vest in a structured manner, with 1/4th vesting on May 20, 2025, and 1/16th vesting every three months thereafter, contingent on the employee's continued service [2] - Standard BioTools, formerly known as Fluidigm Corporation, specializes in next-generation technologies that aid biomedical researchers in developing medicines more efficiently [3] Group 2 - The company utilizes proprietary mass cytometry and microfluidics technologies to provide insights in health and disease, focusing on areas such as oncology, immunology, and immunotherapy [3] - Standard BioTools collaborates with various sectors, including academic, government, pharmaceutical, and clinical laboratories, to address critical needs in translational and clinical research [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34180 STANDARD BIOTOOLS INC. (Exact name of registrant as specified in its charter) Stat ...

Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024 conference call SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while supporting the exe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________ Commission file number: 001-34180 STANDARD BIOTOOLS INC. (Exact name of registrant as specified in its charter) Delaware ...

Standard BioTools Inc. (NASDAQ:LAB) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Peter DeNardo - IR Michael Egholm - CEO and President Jeff Black - CFO Conference Call Participants Operator Hello, and welcome to the Standard BioTools' Third Quarter 2023 Financial Results Conference Call. As a reminder this conference is being recorded. It is now my pleasure to introduce your host Peter DeNardo, Investor Relations. Thank you. Mr. DeNardo, you may begin. Peter DeNardo Than ...